MA51043A - Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée - Google Patents

Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée

Info

Publication number
MA51043A
MA51043A MA051043A MA51043A MA51043A MA 51043 A MA51043 A MA 51043A MA 051043 A MA051043 A MA 051043A MA 51043 A MA51043 A MA 51043A MA 51043 A MA51043 A MA 51043A
Authority
MA
Morocco
Prior art keywords
class
ras protein
hla antigen
antigenic specificity
mutated ras
Prior art date
Application number
MA051043A
Other languages
English (en)
Inventor
Gal Cafri
Yong-Chen Lu
Steven A Rosenberg
Rami Yoseph
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MA51043A publication Critical patent/MA51043A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
MA051043A 2017-12-04 2018-12-03 Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée MA51043A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762594244P 2017-12-04 2017-12-04

Publications (1)

Publication Number Publication Date
MA51043A true MA51043A (fr) 2020-10-14

Family

ID=64949411

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051042A MA51042A (fr) 2017-12-04 2018-12-03 Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée
MA051043A MA51043A (fr) 2017-12-04 2018-12-03 Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA051042A MA51042A (fr) 2017-12-04 2018-12-03 Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée

Country Status (15)

Country Link
US (2) US11466071B2 (fr)
EP (1) EP3720478A1 (fr)
JP (2) JP7385566B2 (fr)
KR (1) KR20200115484A (fr)
CN (1) CN111836638A (fr)
AU (1) AU2018378200A1 (fr)
BR (1) BR112020011111A2 (fr)
CA (1) CA3084246A1 (fr)
CR (1) CR20200287A (fr)
EA (1) EA202091335A1 (fr)
IL (1) IL275031A (fr)
MA (2) MA51042A (fr)
MX (1) MX2020005765A (fr)
SG (1) SG11202005236QA (fr)
WO (1) WO2019112941A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3063905A1 (fr) * 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies et procedes d'utilisation
EP3914270A4 (fr) * 2019-01-25 2023-01-11 The Trustees of the University of Pennsylvania Compositions et procédés de ciblage de ras mutants
KR20210130189A (ko) 2019-02-20 2021-10-29 프레드 헛친슨 켄서 리서치 센터 Ras 신항원에 특이적인 결합 단백질 및 이의 용도
EP3760217A1 (fr) * 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Thérapie cellulaire ou génique basée sur le récepteur de lymphocytes t cd5 spécifiques
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
AU2021221138A1 (en) * 2020-02-12 2022-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA Class I-restricted T cell receptors against RAS with G12D mutation
CN115315441A (zh) * 2020-02-14 2022-11-08 美国卫生和人力服务部 针对含有g12v突变的ras的hla i类限制性t细胞受体
US20230159614A1 (en) * 2020-02-26 2023-05-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation
CN116710111A (zh) * 2020-10-02 2023-09-05 美国卫生和人力服务部 针对含有g13d突变的ras的hla ii类限制性dq t细胞受体
KR102488353B1 (ko) * 2020-10-08 2023-01-12 부산대학교 산학협력단 돌연변이 kras를 표적하는 펩타이드 및 이의 용도
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors containing polycistronic cassettes and methods for using them
AU2022283277A1 (en) * 2021-05-25 2023-12-14 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
CN118574843A (zh) 2022-01-21 2024-08-30 T-Knife 股份有限公司 以可检测的亲和力结合特异性肽的抗原识别构建体和对kras具有抗原特异性的t细胞受体以及相应的核酸序列、载体、宿主细胞、药物组合物和试剂盒
WO2023150562A1 (fr) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Méthodes d'activation et d'expansion de lymphocytes t
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
CN115850444A (zh) * 2022-09-15 2023-03-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN115960204B (zh) * 2022-11-04 2023-08-25 新景智源生物科技(苏州)有限公司 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
ES2876176T3 (es) * 2010-09-21 2021-11-12 The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso
WO2012129201A1 (fr) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de mise en croissance de lymphocytes infiltrant une tumeur dans contenants perméables au gaz
HUE065689T2 (hu) * 2014-11-26 2024-06-28 The United States Of America Anti-mutált KRAS T sejt receptorok
EP3350213B1 (fr) * 2015-09-15 2021-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs de lymphocytes t reconnaissant les gènes kras mutés limités en hla-cw8
HUE053674T2 (hu) * 2015-12-23 2021-07-28 Medigene Immunotherapies Gmbh Antigén-specifikus TCR receptorok új generációja
EP3394092A1 (fr) * 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center Récepteurs des cellules t à forte affinité et leurs utilisations
US20210052642A1 (en) * 2017-12-04 2021-02-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of enriching cell populations for cancer-specific t cells using in vitro stimulation of memory t cells

Also Published As

Publication number Publication date
KR20200115484A (ko) 2020-10-07
IL275031A (en) 2020-07-30
EP3720478A1 (fr) 2020-10-14
CN111836638A (zh) 2020-10-27
JP2021505136A (ja) 2021-02-18
MX2020005765A (es) 2020-09-25
JP7385566B2 (ja) 2023-11-22
CR20200287A (es) 2020-11-11
US11466071B2 (en) 2022-10-11
AU2018378200A1 (en) 2020-07-02
SG11202005236QA (en) 2020-07-29
CA3084246A1 (fr) 2019-06-13
EA202091335A1 (ru) 2020-10-15
MA51042A (fr) 2020-10-14
US20210079058A1 (en) 2021-03-18
BR112020011111A2 (pt) 2020-11-17
WO2019112941A1 (fr) 2019-06-13
JP2023175703A (ja) 2023-12-12
US20230026180A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
MA51043A (fr) Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
CY1125008T1 (el) Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων
MA49270A (fr) Récepteurs de liaison à l'antigène améliorés
CY1121539T1 (el) Ειδικοι για κλαυδiνη-6 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
CY1122188T1 (el) Θεραπευτικη αντιμετωπιση της προοδευτικης οστεοποιους ινοδυσπλασιας
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
MA46113A (fr) Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3)
SG11202101685XA (en) Bcma chimeric antigen receptor based on single domain antibody and use thereof
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
DK3592379T3 (da) Universelle anti-cd22-kimære antigenreceptor-modificerede immunceller
EA202190542A1 (ru) Сконструированные биспецифические белки
CO2019013654A2 (es) Receptores de antígenos quiméricos que se dirigen a flt3
CY1121944T1 (el) Σταθεροποιημενες πρωτεϊνες για ανοσοποιηση εναντι staphylococcus aureus
PE20140612A1 (es) Estratificaciones a base de bcma y terapia para pacientes con mieloma multiple
RU2017129721A (ru) АНТИТЕЛА ПРОТИВ αβTCR
IL282641A (en) Single-region antibodies that bind human serum albumin
IL284091A (en) Antibodies neutralize the type 2 immunoglobulin-like leukocyte receptor
DK3806903T5 (da) Cd79a kimæriske antigenreceptorer
EP3705494A3 (fr) Anticorps contre les protéines frizzled et leurs méthodes d'utilisation
PE20230381A1 (es) Proteina de union a rgma
IL285587A (en) Chimeric antigen receptors respond to hypoxia
MA53094A (fr) Protéine de liaison à l'antigène anti-steap1
MA51750A (fr) Appareil d'égalisation d'usure pour cyclones